	Notes	As at 31 March 2025	As at 31 March 2024
ASSETS		31 Water 2023	31 WIAICH 2024
Non-current assets			
Property, plant and equipment	3	73,084	80,396
Total non-current assets	_	73,084	80,396
Current assets			
Financial assets			
i. Trade receivables	4	20,40,038	10,33,517
ii. Cash and cash equivalents	5	5,83,610	2,70,361
Other current assets	6	1,28,012	75,196
Total current assets	_	27,51,660	13,79,074
Total assets	=	28,24,744	14,59,470
EQUITY AND LIABILITIES			
Equity			
Equity share capital	7	1,50,000	1,50,000
Other equity		19,72,982	7,59,855
Total equity	_	21,22,982	9,09,855
LIABILITIES			
Non-current liability			
Deferred tax liabilities (net)	_	10,503	10,728
Total non-current liability	_	10,503	10,728
Current liabilities			
Financial liabilities			
i. Trade payables	8	1,44,440	2,76,358
ii. Other financial liabilities	9	54,000	88,251
Other current liabilities	10	86,409	1,17,653
Current tax liabilities	11 _	4,06,409	56,625
Total current liabilities	_	6,91,259	5,38,887
Total liabilities	_	7,01,762	5,49,615
Total equity and liabilities	_	28,24,744	14,59,470

Benny Thomas Vice President & CFO

TrialStat Solutions Inc Statement of Profit and Loss for the year ended 31 March 2025 (All amounts are in CAD, unless stated otherwise)

	Notes	For the year ended 31 March 2025	For the year ended 31 March 2024
Revenue from operations	12	32,12,573	17,14,547
Other income	13	38,997	15,580
Total income		32,51,570	17,30,127
Expenses			
Employee benefits expenses	14	10,60,121	9,69,226
Finance costs	15	-	16,987
Depreciation and amortization expense	16	64,382	53,829
Other expenses	17	4,74,818	3,80,974
Total expenses		15,99,321	14,21,016
Profit before tax		16,52,249	3,09,111
Tax expense			
- Current tax		4,39,347	85,072
-Deferred tax		(225)	11,809
Total tax expense		4,39,122	96,881
Profit for the year		12,13,127	2,12,230
Other comprehensive Income/(loss)			
Items that will not be reclassified to profit or loss			
Exchange differences on translation of foreign operations		-	-
Other comprehensive income for the year, net of tax		-	-
Total comprehensive income for the year		12,13,127	2,12,230

Benny Thomas Vice President & CFO

TrialStat Solutions Inc Statement of Cash Flows for the year ended 31 March 2025 (All amounts are in CAD, unless stated otherwise)

	For the year ended 31 March 2025	For the year ended 31 March 2024
A. Cash flow from operating activities		
Profit before tax	16,52,249	3,09,111
Adjustments:		
Depreciation and amortisation expense	64,382	53,829
Finance cost	-	16,987
Unrealised loss	-	(1)
	64,382	70,815
Operating cash flow before working capital changes	17,16,631	3,79,926
(Increase)/Decrease in trade receivables and other current assets	(10,59,337)	(40,570)
(Decrease)/Increase in trade payables, provisions and other liabilities	(1,97,413)	1,69,911
Cash generated in operations	4,59,881	5,09,267
Income tax paid	-89,563	-31,310
Net cash generated from operating activities (A)	3,70,318	4,77,957
B. Cash flow from investing activities		
Purchase of property, plant and equipment	(57,070)	(41,177)
Net cash used in investing activities (B)	(57,070)	(41,177)
C. Cash flow from financing activities		
Repayment of borrowings	-	(4,46,952)
Interest paid	_	(1,07,426)
Net cash generated from financing activities (C)		(5,54,378)
Net increase in cash and cash equivalents (A+B+C)	3,13,249	(1,17,598)
Add: cash and cash equivalents at the beginning of year	2,70,361	3,87,959
Cash and cash equivalents at the end of the year	5,83,610	2,70,361

Benny Thomas
Vice President & CFO

TrialStat Solutions Inc

Statement of Change in Equity for the year ended 31 March 2025

(All amounts are in CAD, unless stated otherwise)

A. Equity share capital

Balance as at 1 April 2023	1,50,000
Additions during the year	<u> </u>
Balance as at 31 March 2024	1,50,000
Additions during the year	
Balance as at 31 March 2025	1,50,000

B. Other Equity

	Reserves and Surplus	
	Retained earnings	Total
Balance as at 1 April 2023	5,47,625	5,47,625
Profit for the year	2,12,230	2,12,230
Total comprehensive income for the year	2,12,230	2,12,230
Balance as at 31 March 2024	7,59,855	7,59,855

	Reserves and Surplus		
	Retained earnings	Total	
Balance as at 1 April 2024	7,59,855	7,59,855	
Profit for the year	12,13,127	12,13,127	
Total comprehensive income for the year	12,13,127	12,13,127	
Balance as at 31 March 2025	19,72,982	19,72,982	

Benny Thomas Vice President & CFO

(All amounts are in CAD, unless stated otherwise)

Note 1: Corporate information

TrialStat Solutions Inc ("the Company") was incorporated on October 18, 2010 in the Canada. The Company is a wholly owned subsidiary of Jubilant Biosys Innovative Research Services Pte Limited, a company incorporated in Singapore. The Company engaged into the activities of providing cloud/SaaS software for clinical trials.

Note 2: Material accounting policies

This note provides a list of the material accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation

(i) Statement of compliance

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) Historical cost convention

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is Canadian Dollars ("CAD"). These financial statements are presented in CAD.

(c) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current and non-current classification of assets and liabilities.

TrialStat Solutions Inc Notes to the financial statements for the year ended 31 March 2025

(All amounts are in CAD, unless stated otherwise)

Note 3: Property, plant and equipment

Description	Office equipment	Total
Gross carrying value as at 1 April 2023	2,78,256	2,78,256
Additions during the year	41,177	41,177
Gross carrying value as at 31 March 2024	3,19,433	3,19,433
Accumulated depreciation as at 1 April 2023	1,85,208	1,85,208
Depreciation charge for the year	53,829	53,829
Accumulated depreciation as at 31 March 2024	2,39,037	2,39,037
Net carrying value as at 31 March 2024	80,396	80,396

Description	Office equipment	Total	
Gross carrying value as at 1 April 2024	3,19,433	3,19,433	
Additions during the year	57,070	57,070	
Gross carrying value as at 31 March 2025	3,76,503	3,76,503	
Accumulated depreciation as at 1 April 2024	2,39,037	2,39,037	
Depreciation charge for the year	64,382	64,382	
Accumulated depreciation as at 31 March 2025	3,03,419	3,03,419	
Net carrying value as at 31 March 2025	73,084	73,084	

Note 4: Trade receivables

	As at	As at
	31 March 2025	31 March 2024
Unsecured, considered good		
Trade receivables	20,40,038	10,33,517
Total trade receivables	20,40,038	10,33,517

Note 5: Cash and cash equivalents

	As at	As at
	31 March 2025	31 March 2024
Balances with banks		
- in current accounts	5,83,610	2,70,361
Total cash and cash equivalents	5,83,610	2,70,361

Note 6: Other current assets

	As at	As at
	31 March 2025	31 March 2024
Prepaid expenses	1,25,012	29,537
Advance recoverable from related parties	-	42,659
Staff advance	3,000	3,000
Total other current assets	1,28,012	75,196

TrialStat Solutions Inc Notes to the financial statements for the year ended 31 March 2025 (All amounts are in CAD, unless stated otherwise)

Note 7: Share Capital

	As at 31 March 2025	As at 31 March 2024	
Issued, subscribed and paid up			
1,50,000 (31 March 2024: 1,50,000) Equity shares of CAD 1 each	1,50,000	1,50,000	

- 1) The Company has only one class of shares referred to as equity shares of CAD 1 each. Each holder of equity shares is entitled to one vote per share.
- 2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

Jubilant Biosys Innovative Research Services Pte. Limited

	As :	at	As	at	
	31 Marc	31 March 2025		31 March 2024	
	No. of shares	% holding in the class	No. of shares	% holding in the class	
Name of the Shareholder					
Jubilant Biosys Innovative Research Services Pte. Limited	1,50,000	100%	1,50,000	100%	
	125		1 20		
	As:	••	1 20	at	
	31 Marc	h 2025	31 Mar	ch 2024	
	No. of shares	h 2025 Amount	31 Mar No. of shares	ch 2024 Amount	
Number of shares at the beginning of the year					
Number of shares at the beginning of the year Add: Shares issued during the year	No. of shares	Amount	No. of shares	Amount	
ę ę ,	No. of shares	Amount	No. of shares	Amount 1,50,000	
Add: Shares issued during the year	No. of shares 1,50,000	Amount 1,50,000	No. of shares 1,50,000	Amount 1,50,000	
Add: Shares issued during the year Number of shares at the end of the year	No. of shares 1,50,000	Amount 1,50,000 - 1,50,000	No. of shares 1,50,000 - 1,50,000	Amount 1,50,000	
Add: Shares issued during the year Number of shares at the end of the year	No. of shares 1,50,000 - 1,50,000	Amount 1,50,000 - 1,50,000	No. of shares 1,50,000 - 1,50,000 As	Amount 1,50,000 - 1,50,000	

100%

100%

1,50,000

1,50,000

TrialStat Solutions Inc Notes to the financial statements for the year ended 31 March 2025 (All amounts are in CAD, unless stated otherwise)

Note 8: Trade payables

	As at 31 March 2025	As at 31 March 2024
Current		
Trade payables	1,44,440	2,76,358
Total trade payables	1,44,440	2,76,358

Note 9: Other financial liabilities

	As at	As at
	31 March 2025	31 March 2024
Current		
Employee benefit payable	54,000	88,251
Total other current financial liabilities	54,000	88,251

Note 10: Other current liabilities

	As at	As at
	31 March 2025	31 March 2024
Income received in advance/unearned income	26,686	94,619
Statutory dues payables	59,723	23,034
Total other current liabilities	86,409	1,17,653

Note 11: Current tax liabilities

	As at	As at	
	31 March 2025	31 March 2024	
Opening balance	56,625	2,863	
Add: Current tax payable for the year	4,39,347	56,625	
Less: Taxes paid	(89,563)	(2,863)	
Closing balance	4,06,409	56,625	

TrialStat Solutions Inc Notes to the financial statements for the year ended 31 March 2025 (All amounts are in CAD, unless stated otherwise)

Note 12: Revenue from operations

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Sale of services	29,39,835	14,62,553
Other operating revenue	2,72,738	2,51,994
Total revenue from operations	32,12,573	17,14,547

Note 13: Other income

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Net foreign exchange gain	38,997	15,580
Total other income	38,997	15,580

Note 14: Employee benefits expenses

Particulars	For the year ended	For the year ended
1 at ticulars	31 March 2025	31 March 2024
Salaries, wages, bonus, gratuity and allowances	10,19,501	9,31,174
Staff welfare expenses	40,620	38,052
Total employee benefits expenses	10,60,121	9,69,226

Note 15: Finance costs

Particulars	For the year ended	For the year ended
1 at ticulars	31 March 2025	31 March 2024
Interest expense	=	16,987
Total finance costs	-	16,987

Note 16: Depreciation and amortization expense

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Depreciation of property, plant and equipment	64,382	53,829
Total depreciation and amortisation expense	64,382	53,829

Note 17: Other expenses

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Processing charges	39,369	14,357
Travel and conveyance	1,03,924	84,968
Communication expenses	65,257	66,829
Legal and professional fees	94,282	5,083
Bank charges	5,524	6,137
Printing and stationery	68	-
Repair and maintenance	1,830	3,887
Business/Sales Promotion	6,001	33,179
Meeting & Conference expenses	92,882	75,888
Subscription	63,556	90,437
Rates & Taxes	2,125	209
Total other expenses	4,74,818	3,80,974